This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Jamen, F. Articles by Bertrand, G. Search for Related Content PubMed PubMed Citation Articles by Jamen, F. Articles by Bertrand, G.

Pituitary Adenylate Cyclase-Activating Polypeptide Receptors Mediating Insulin Secretion in Rodent Pancreatic Islets Are Coupled to Adenylate Cyclase But Not to PLC

Unité Propre de Recherche 9023, Centre National de la Recherche Scientifique, 34094 Montpellier Cedex 05, France

Address all correspondence and requests for reprints to: Gyslaine Bertrand, Unité Propre de Recherche 9023, Centre National de la Recherche Scientifique, 141 rue de la Cardonille, 34094 Montpellier Cedex 05, France. E-mail: . bertrand{at}montp.inserm.fr

Pituitary adenylate cyclase-activating polypeptide (PACAP) is a potentiator of glucose-induced insulin secretion. PACAP binds to a PACAP-specific receptor (PAC1) and to VPAC receptors (VPAC1 and VPAC2), which share high affinity for vasoactive intestinal polypeptide (VIP). In the present study, the molecular expression of PACAP receptor isoforms and the signaling pathways involved in the insulin secretory effect of PACAP were investigated in isolated rat and mouse pancreatic islets. mRNA encoding PAC1-short, -hop, and -very short variants, as well as VPAC1 and VPAC2, were expressed in pancreatic islets. PACAP and VIP were equipotent in potentiating glucose-induced insulin release. Both peptides were also equipotent in increasing cAMP production, but PACAP was more efficient than VIP. Unlike carbachol, PACAP and VIP had no effect on inositol phosphate production. In the PAC1-deficient mouse, the insulinotropic effect of PACAP was reduced, and its differential effect on cAMP production was abolished, whereas the effects of VIP remained unchanged. These results clearly show that the insulinotropic effect of PACAP involved both VPAC and PAC1. The PAC1 variants expressed in rat and mouse pancreatic islets seem to be coupled to adenylate cyclase but not to PLC.

This article has been cited by other articles:

				D. Vaudry, A. Falluel-Morel, S. Bourgault, M. Basille, D. Burel, O. Wurtz, A. Fournier, B. K. C. Chow, H. Hashimoto, L. Galas, et al. Pituitary Adenylate Cyclase-Activating Polypeptide and Its Receptors: 20 Years after the Discovery Pharmacol. Rev., September 1, 2009; 61(3): 283 - 357. [Abstract] [Full Text] [PDF]

				C. Broca, J. Quoyer, S. Costes, N. Linck, A. Varrault, P.-M. Deffayet, J. Bockaert, S. Dalle, and G. Bertrand {beta}-Arrestin 1 Is Required for PAC1 Receptor-mediated Potentiation of Long-lasting ERK1/2 Activation by Glucose in Pancreatic {beta}-Cells J. Biol. Chem., February 13, 2009; 284(7): 4332 - 4342. [Abstract] [Full Text] [PDF]

				S. S. Qader, J. Jimenez-Feltstrom, M. Ekelund, I. Lundquist, and A. Salehi Expression of islet inducible nitric oxide synthase and inhibition of glucose-stimulated insulin release after long-term lipid infusion in the rat is counteracted by PACAP27 Am J Physiol Endocrinol Metab, May 1, 2007; 292(5): E1447 - E1455. [Abstract] [Full Text] [PDF]

				M. Delgado, D. Pozo, and D. Ganea The Significance of Vasoactive Intestinal Peptide in Immunomodulation Pharmacol. Rev., June 1, 2004; 56(2): 249 - 290. [Abstract] [Full Text] [PDF]

				L. Rachdi, J.-C. Marie, and R. Scharfmann Role for VPAC2 Receptor-Mediated Signals in Pancreas Development Diabetes, January 1, 2003; 52(1): 85 - 92. [Abstract] [Full Text] [PDF]